Novo Nordisk's blockbuster Ozempic wins FDA label boost with CV indication

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jan 17, 2020 at 11:22 AM.

  1. #1 cafead, Jan 17, 2020 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,039
    Likes Received:
    3
    via Novo Nordisk’s blockbuster weekly injectable formulation of semaglutide — Ozempic — has secured an even more formidable label. Apart from its ability to stimulate insulin production in patients with diabetes, the FDA has now also endorsed its ability to reduce the risk of major adverse cardiovascular events.

    article source
     
    Quote

Reply to Thread